百利天恒 延迟港股上市

Core Viewpoint - Baili Tianheng has announced a delay in its global offering and will not proceed with the public offering as originally planned due to current market conditions [2][6]. Group 1: Announcement Details - The public offering originally scheduled from November 7 to noon on November 12 has been halted, and all application funds for the public offering will be fully refunded, with the refund process expected to be completed by November 17 [6]. - The decision to delay the global offering does not affect the company's current business operations, and the company is carefully evaluating the timeline for the global offering and listing [7]. Group 2: Financial Performance - For the first three quarters of 2025, Baili Tianheng reported a revenue of 2.066 billion yuan, a year-on-year decrease of 63.52%, and a net profit attributable to shareholders of -495 million yuan [10]. - The company has developed innovative drug research platforms, including the HIRE-ADC platform, GNC platform, and HIRE-ARC platform, which are expected to enhance tumor treatment through combination therapies in the future [10]. Group 3: Company Background - Baili Tianheng focuses on cutting-edge global biopharmaceutical fields, aiming to address unmet clinical needs, particularly in the area of tumor macromolecule therapy, and possesses leading innovative research and development capabilities [9].